Published in Physician Business Week, February 13th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Basilea Pharmaceutica.
Report 1: Basilea Pharmaceutica, Ltd., (BSLN) announced the opening of two primary-treatment phase III clinical trials for isavuconazole (BAL8557) in patients with invasive systemic fungal infections caused by yeasts and molds.
Isavuconazole is Basilea's third compound to enter phase III development.
The global trial program for isavuconazole (BAL8557) focuses on patients with invasive candidiasis including candidemia and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.